

12<sup>th</sup>

ANNUAL ACUTE  
**LEUKEMIA**  
MEETING 2023

From 5<sup>th</sup> to 7<sup>th</sup>  
OCT

*In person  
& virtual event*

**DIRECTOR**

**Dr. Adolfo de la Fuente**  
*MD Anderson Cancer Center Madrid, España*

[www.mdanderson.es/cursoleucemia](http://www.mdanderson.es/cursoleucemia)

MDAnderson  
~~Cancer~~ Center  
Madrid • España



## SCIENTIFIC COMMITTEE

**Dr. Ángela Figuera**

*Hospital Universitario de La Princesa, Madrid, Spain*

**Dr. Valentín García Gutiérrez**

*Hospital Universitario Ramón y Cajal, Madrid, Spain*

**Dr. Guillermo García-Manero**

*MD Anderson Cancer Center Madrid, Spain*

**Dr. Adrián Mosquera**

*Hospital Clínico Universitario, Santiago de Compostela, Spain*

**Dr. Mayte Olave**

*Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain*

**Dr. Joaquín Sánchez**

*Hospital Universitario Reina Sofía, Córdoba, Spain*

**Dr. Mar Tormo**

*Hospital Clínico Universitario de Valencia, Spain*

**Dr. David Valcárcel**

*Hospital valle de Hebron Barcelona. Institute of Oncology, Hospital Quirónsalud Barcelona, Spain*

**Dr. Claudio Cerchione**

*IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola, Italy*

**Dr. Naval Daver**

*MD Anderson Cancer Center, Houston, USA*

**Dr. Alessandro Isidori**

*Marche Nord Hospital, Pesaro, Italy*

**Dr. Elias Jabbour**

*MD Anderson Cancer Center, Houston, USA*

## AMBASSADORS

**Breno Moreno de Gusmão**

*Beneficência Portuguesa de São Paulo, São Paulo, Brasil*

*LATAM Ambassador*

14:50 - 15:00

## WELCOME

15:00 - 16:00

## MEET THE EXPERT 1 **Key points in the treatment of Polycythaemia Vera. Interactive clinical case study**

*Chair:*

*Dr. Valentín García Gutiérrez, Hospital Universitario Ramón y Cajal, Madrid, Spain*

16:00 - 16:55

## SESSION 1 **LMA 2 Target therapies - I**

*Chairs:*

*Dr. Naval Daver, MD Anderson Cancer Center, Houston, USA*

*Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain*

16:00 - 16:20

### **Targeting IDH 1**

*Dr. Courtney DiNardo, MD Anderson Cancer Center, Houston, USA*

16:20 - 16:40

### **FLT 3 inhibitors in relapse setting, biomarkers and mechanism of resistance**

*Dr. Naval Daver, MD Anderson Cancer Center, Houston, USA*

16:40 - 16:55

### **Discussion**

16:55 - 17:50

**SESSION 2 ALL session**

*Chairs:*

Dr. Elias Jabbour, MD Anderson Cancer Center, Houston, USA  
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain  
Dr. Alessandro Isidori, Marche Nord Hospital, Pesaro, Italy

16:55 - 17:15

**Ph-positive, ready for Chemo-free approach**

Dr. Elias Jabbour, MD Anderson Cancer Center, Houston, USA

17:15 - 17:35

**Management of the elderly patient of ALL**

Dr. María Calbacho, Hospital Universitario 12 de Octubre, Madrid, Spain

17:35 - 17:50

**Discussion**

17:50 - 18:10

*Coffee break*

18:10 - 19:25

**SESSION 3 Diagnosis and preclinical management of leukaemia**

*Chairs:*

Dr. Joaquín Sánchez, Hospital Universitario Reina Sofía, Córdoba, Spain  
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain

18:10 - 18:30

**ELN-2022 risk stratification and the challenge of working with two AML classifications**

Dr. Jordi Sierra, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

18:30 - 18:50

**MRD determination and treatment algorithms**

Dr. Eva Barragán, Hospital Universitario y Politécnico La Fe, Valencia, Spain

18:50 - 19:10

**Ex-Vivo tridimensional models for drug-sensitivity studies in AML**

Dr. Juana Serrano, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain

19:10 - 19:25

**Discussion**

19:25 - 20:25

**DISCUSSION Induction therapy in transplant candidates. Intensive chemotherapy versus venetoclax-based therapy**

*Chairs:*

Dr. Mar Tormo, Hospital Clínico Universitario de Valencia, Spain  
Dr. Ángela Figuera, Hospital Universitario de La Princesa, Madrid, Spain  
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain  
Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, USA

**Transplant candidate patient Intensive Induction**

YES - Dr. Josefina Serrano, Hospital Universitario Reina Sofía, Córdoba, Spain  
NO - Dr. Jordi Esteve, Hospital Clínic de Barcelona, Spain

**Discussion**

08:30 - 09:25

**SESSION 4 Myelodysplasia 1**

*Chairs:*

Dr. Guillermo García-Manero, *MD Anderson Cancer Center, Houston, USA*  
Dr. Mar Tormo, *Hospital Clínico Universitario de Valencia, Spain*

08:30 - 08:50

**Altered pathways and target therapies in MDS**

Dr. Joaquín Sánchez, *Hospital Universitario Reina Sofía, Córdoba, Spain*

08:50 - 09:10

**Treatment of CCUS**

Dr. Guillermo García-Manero, *MD Anderson Cancer Center, Houston, USA*

09:10 - 09:25

**Discussion**

09:25 - 10:40

**SESSION 5 Chronic myeloproliferative neoplasms**

*Chairs:*

Dr. Valentín García Gutiérrez, *Hospital Universitario Ramón y Cajal, Madrid, Spain*  
Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

09:25 - 09:45

**New developments in the management of myelofibrosis**

Dr. Valentín García Gutiérrez, *Hospital Universitario Ramón y Cajal, Madrid, Spain*

09:45 - 10:05

**Management of advanced stage chronic myeloid leukaemia**

Dr. Guillermo Ortí, *Hospital Universitario Vall d'Hebron, Barcelona, Spain*

10:05 - 10:25

**aCML and CNL. Diagnostic approach and treatment**

Dr. Gonzalo Carreño, *Hospital Universitario 12 de Octubre, Madrid, Spain*

10:25 - 10:40

**Discussion**

10:40 - 11:10

*Coffee break*

11:10 - 12:25

**SESSION 6 Immunotherapy**

*Chairs:*

Dr. Alessandro Isidori, *Marche Nord Hospital, Pesaro, Italy*  
Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

11:10 - 11:30

**Driver mutations and immune microenvironment in AML**

Dr. Antonio Curti, *Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola, Bologna, Italy*

11:30 - 11:50

**Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia**

Dr. Charles Craddock, *Queen Elizabeth Hospital Birmingham, London, UK*

11:50 - 12:10

**Integration of immunotherapy into frontline**

Dr. Elias Jabbour, *MD Anderson Cancer Center, Houston, USA*

12:10 - 12:25

**Discussion**

12:25 - 16:55

**SESSION 7 LMA 2 Target therapies - II**

12:25 - 12:45

**Targeting IDH 2**

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

12:45 - 13:05

**FLT 3 Optimal approaches to frontline FLT3 mutated AML**

Dr. Alessandro Isidori, *Marche Nord Hospital, Pesaro, Italy*

13:05 - 13:20

**Discussion**

13:20 - 15:00

*Cocktail*

14:00 - 15:00

## MEET THE EXPERT 3 The mIDH1 AML patient ineligible for intensive chemotherapy: Treatment decisions and practical steps

**Chair:** Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain

14:00 - 14:15

**An update on data for the mIDH1 AML population**  
Dr. Courtney DiNardo, MD Anderson Cancer Center, Houston, USA

14:15 - 14:30

**Testing in time**  
Dr. Pau Montesinos, Hospital Universitario y Politécnico La Fe, Valencia, Spain

14:30 - 14:45

**Case study**  
Dr. Susana Vives, Institut Català d'Oncologia, Badalona, Barcelona, Spain

14:45 - 15:00

**Questions and Answers**

*Session sponsored by Servier*

15:00 - 15:30

## WORKSHOP Learning from the paediatrician

**Chairs:** Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain  
Dr. Mar Tormo, Hospital Clínico Universitario de Valencia, Spain

15:00 - 15:15

**Monoclonals and CAR-T in ALL**  
Dr. Luis Madero, Hospital Universitario Quirónsalud, Madrid, Spain

15:15 - 15:30

**Prevention and management of toxicities in ALL**  
Dr. David Díaz, Hospital Universitario Infantil Niño Jesús Madrid, Spain

15:30 - 16:45

## MEET THE EXPERT 4 Targeting apoptosis. How we treat unfit patients and beyond

**Chairs:** Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain  
Dr. Joaquín Sánchez, Hospital Universitario Reina Sofía, Córdoba, Spain

15:30 - 16:00

**VEN+HMA: long term outcomes, who does the best**  
Dr. Courtney DiNardo, MD Anderson Cancer Center, Houston, USA

16:00 - 16:30

**Venetoclax combination for AML patients and Real world data**  
Dr. Yakir Moshe, Tel Aviv Sourasky Medical Center - Ichilov, Tel Aviv, Israel

16:30 - 16:45

**Discussion**

16:45 - 17:45

## MEET THE EXPERT 5 Chronic Lymphocytic Leukemia

**Chair:** Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain

Dr. Felipe Casado, Hospital General Universitario de Toledo, Spain

17:45 - 18:15

*Coffee break*

18:15 - 18:45

## KEYNOTE LECTURE

**Chairs:** Dr. Joaquín Sánchez, Hospital Universitario Reina Sofía, Córdoba, Spain  
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain  
Dr. Naval Daver, MD Anderson Cancer Center, Houston, USA  
Dr. Guillermo García-Manero, MD Anderson Cancer Center, Houston, USA  
Dr. Joaquín Sánchez, Hospital Universitario Reina Sofía, Córdoba, Spain  
Dr. Alessandro Isidori, Marche Nord Hospital, Pesaro, Italy

**What to do after 1 CR in patients between 65 al 75 yo?**

**An open discussion of options**

Dr. Ángela Figuera, Hospital Universitario de La Princesa, Madrid, Spain

18:45 - 20:00

## SESSION 8 Transplantation in acute leukemia

**Chairs:** Dr. Ángela Figuera, Hospital Universitario de La Princesa, Madrid, Spain  
Dr. Adolfo de la Fuente, MD Anderson Cancer Center Madrid, Spain

18:45 - 19:05

**Graft versus host (GVH) disease and leukemia free survival, can we achieve this?**

Dr. Javier Bolaños, Sidney Kimmel Comprehensive Cancer Centre at Johns Hopkins, Baltimore, USA

19:05 - 19:25

**AML with 10-20% blasts, induction or direct HSCT? Options**

Dr. David Valcárcel, Institute of Oncology, Hospital Quirónsalud Barcelona, Spain

19:25 - 19:45

**Immune based approaches in AML: CART, NK cell, bispecifics moving to the next chapter**

Dr. Naval Daver, MD Anderson Cancer Center, Houston, USA

19:45 - 20:00

**Discussion**

08:30 - 09:45

## SESSION 9 The challenge of maintenance in Acute Myeloid Leukemia. Meet the expert sessions

**Chair:** Dr. Pau Montesinos, *Hospital Universitario y Politécnico La Fe, Valencia, Spain*

08:30 - 08:50

### Immunotherapy maintenance

Dr. Kristoffer Hellstrand, *University of Gothenburg, Göteborg, Sweden*

**Chair:**

Dr. Ángela Figuera, *Hospital Universitario de La Princesa, Madrid, Spain*

08:50 - 09:10

### Oral Azacitidine maintenance

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

**Chair:**

Dr. Alessandro Isidori, *Marche Nord Hospital, Pesaro, Italy*

09:10 - 09:30

### FLT-3 inhibitors maintenance

Dr. Andrius Žučenka, *Vilnius University Hospital Santaros Klinikos, Vilna, Lithuania*

09:30 - 09:45

### Discussion

09:45 - 11:00

## WORKSHOP Blastic plasmacytoid dendritic cell neoplasm (BPDCN)

**Chairs:** Dr. Pau Montesinos, *Hospital Universitario y Politécnico La Fe, Valencia, Spain*  
Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*  
Dr. Alessandro Isidori, *Marche Nord Hospital, Pesaro, Italy*

09:45 - 10:05

### Characterisation and diagnosis

Dr. Claudio Cerchione, *IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST, Meldola, Italy"*

10:05 - 10:25

### Treatment of BPDCN

Dr. Josefina Serrano, *Hospital Univ. Reina Sofía, Córdoba, Spain*

10:25 - 10:45

### Real-life experience and practical aspects

Dr. Pedro Paúl, *Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain*

10:45 - 11:00

### Conclusions

11:00 - 11:30

### Coffee break

11:30 - 12:45

## SESSION 10 Artificial intelligence

**Chairs:**

Dr. Adrián Mosquera, *Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain*  
Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

11:30 - 11:50

### Computer vision for automatic diagnosis of AML from bone marrow smears

Dr. Jan-Niklas Eckardt, *University Hospital Carl Gustav Carus, Dresden, Germany*

11:50 - 12:10

### Subclassification of primary and secondary AML based on genomic profiles using AI

Dr. Torsten Haferlach, *Munich Leukemia Laboratory, Munich, Germany*

12:10 - 12:30

### Risk prediction in myelofibrosis and MDS with machine-learning tools

Dr. Adrián Mosquera, *Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain*

12:30 - 12:45

### Discussion

12:45 - 13:40

## SESSION 11 High Risk AML

*Chairs:*

Dr. Alessandro Isidori, *Marche Nord Hospital, Pesaro, Italy*  
Dr. Claudio Cerchione, *IRCCS Istituto Romagnolo per lo Studio dei Tumori  
"Dino Amadori" - IRST, Meldola, Italy"*

12:45 - 13:05

### Management of high-risk AML

Dr. Pau Montesinos, *Hospital Universitario y Politécnico La Fe, Valencia, Spain*

13:05 - 13:25

### Vyxeos in young patients with Secondary AML

Dr. Priyanka Mehta, *University Hospitals Bristol and Weston, Bristol, UK*

13:25 - 13:40

### Discussion

13:40 - 14:35

## SESSION 12 Myelodysplasia 2

*Chairs:*

Dr. David Valcárcel, *Institute of Oncology, Hospital Quirónsalud Barcelona, Spain*  
Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

13:40 - 14:00

### New approaches for anemia in MDS

Dr. Guillermo García-Manero, *MD Anderson Cancer Center, Houston, USA*

14:00 - 14:20

### High risk MDS

Dr. Mar Tormo, *Hospital Clínico Universitario de Valencia, Spain*

14:20 - 14:35

### Discussion

14:35 - 14:40

## CLOSING Conclusions and closing

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*

## EL RETO

*Evaluators:*

Dr. Adolfo de la Fuente, *MD Anderson Cancer Center Madrid, Spain*  
Dr. María Ángeles Foncillas, *Hospital Universitario Infanta Leonor, Madrid, Spain*  
Dr. Ana Alfonso, *Clínica Universidad de Navarra, Pamplona, Spain*

# 12<sup>th</sup> ANNUAL ACUTE LEUKEMIA MEETING

From **5<sup>th</sup> to 7<sup>th</sup>** OCT 2023

## SPONSORS

### PLATINUM



### GOLD



### SILVER



### BRONZE



### COLABORATORS



## ORGANIZED BY

MD Anderson  
~~Cancer Center~~  
Fundación • España

## ACCREDITATION

Credits requested from the Continuing Education Commission  
of Health Professions of the Community of Madrid

## AUSPICE



## VENUE

Auditorio Fundación MD Anderson Cancer Center Spain  
C/ Arturo Soria 270. 28033 Madrid

## STREAMING

## TECHNICAL SECRETARY

doctaforum  
MEDICAL MARKETING SPECIALISTS

(+34) 91 372 02 03  
e-mail: [cursoleucemia@doctaforum.com](mailto:cursoleucemia@doctaforum.com)  
[www.mdanderson.es/cursoleucemia](http://www.mdanderson.es/cursoleucemia)